- Home
- CNEY vs ONCO Comparison
CNEY vs ONCO Comparison
Compare CNEY & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNEY
- ONCO
- Stock Information
- Founded
- CNEY 2018
- ONCO 2018
- Country
- CNEY China
- ONCO United States
- Employees
- CNEY N/A
- ONCO N/A
- Industry
- CNEY Major Chemicals
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- CNEY Industrials
- ONCO Health Care
- Exchange
- CNEY Nasdaq
- ONCO Nasdaq
- Market Cap
- CNEY 2.1M
- ONCO 1.8M
- IPO Year
- CNEY 2021
- ONCO 2022
- Fundamental
- Price
- CNEY $0.13
- ONCO $0.07
- Analyst Decision
- CNEY
- ONCO
- Analyst Count
- CNEY 0
- ONCO 0
- Target Price
- CNEY N/A
- ONCO N/A
- AVG Volume (30 Days)
- CNEY 504.6K
- ONCO 9.4M
- Earning Date
- CNEY 01-01-0001
- ONCO 05-19-2025
- Dividend Yield
- CNEY N/A
- ONCO N/A
- EPS Growth
- CNEY N/A
- ONCO N/A
- EPS
- CNEY N/A
- ONCO N/A
- Revenue
- CNEY $50,957,974.00
- ONCO $1,870,605.00
- Revenue This Year
- CNEY N/A
- ONCO N/A
- Revenue Next Year
- CNEY N/A
- ONCO N/A
- P/E Ratio
- CNEY N/A
- ONCO N/A
- Revenue Growth
- CNEY N/A
- ONCO N/A
- 52 Week Low
- CNEY $0.12
- ONCO $0.07
- 52 Week High
- CNEY $1.60
- ONCO $21.40
- Technical
- Relative Strength Index (RSI)
- CNEY 32.47
- ONCO 18.10
- Support Level
- CNEY $0.12
- ONCO $0.07
- Resistance Level
- CNEY $0.14
- ONCO $0.08
- Average True Range (ATR)
- CNEY 0.01
- ONCO 0.02
- MACD
- CNEY 0.00
- ONCO 0.01
- Stochastic Oscillator
- CNEY 28.97
- ONCO 5.88
About CNEY CN Energy Group Inc.
CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.